DE69841549D1 - Verfahren und zubereitungen zur zerstörung bestimmter proteine - Google Patents
Verfahren und zubereitungen zur zerstörung bestimmter proteineInfo
- Publication number
- DE69841549D1 DE69841549D1 DE69841549T DE69841549T DE69841549D1 DE 69841549 D1 DE69841549 D1 DE 69841549D1 DE 69841549 T DE69841549 T DE 69841549T DE 69841549 T DE69841549 T DE 69841549T DE 69841549 D1 DE69841549 D1 DE 69841549D1
- Authority
- DE
- Germany
- Prior art keywords
- ansamycin
- compounds
- targeting
- alone
- moiety
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 230000006378 damage Effects 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- ATEBXHFBFRCZMA-VXTBVIBXSA-N rifabutin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC(=C2N3)C(=O)C=4C(O)=C5C)C)OC)C5=C1C=4C2=NC13CCN(CC(C)C)CC1 ATEBXHFBFRCZMA-VXTBVIBXSA-N 0.000 abstract 4
- 229960000885 rifabutin Drugs 0.000 abstract 4
- 230000008685 targeting Effects 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 abstract 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 abstract 2
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 101100016370 Danio rerio hsp90a.1 gene Proteins 0.000 abstract 1
- 101100285708 Dictyostelium discoideum hspD gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101100071627 Schizosaccharomyces pombe (strain 972 / ATCC 24843) swo1 gene Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012829 chemotherapy agent Substances 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229960005309 estradiol Drugs 0.000 abstract 1
- 229930182833 estradiol Natural products 0.000 abstract 1
- 239000003550 marker Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 230000008684 selective degradation Effects 0.000 abstract 1
- 229960001603 tamoxifen Drugs 0.000 abstract 1
- 229960003604 testosterone Drugs 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- QDLHCMPXEPAAMD-QAIWCSMKSA-N wortmannin Chemical compound C1([C@]2(C)C3=C(C4=O)OC=C3C(=O)O[C@@H]2COC)=C4[C@@H]2CCC(=O)[C@@]2(C)C[C@H]1OC(C)=O QDLHCMPXEPAAMD-QAIWCSMKSA-N 0.000 abstract 1
- QDLHCMPXEPAAMD-UHFFFAOYSA-N wortmannin Natural products COCC1OC(=O)C2=COC(C3=O)=C2C1(C)C1=C3C2CCC(=O)C2(C)CC1OC(C)=O QDLHCMPXEPAAMD-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4645197P | 1997-05-14 | 1997-05-14 | |
| PCT/US1998/009805 WO1998051702A1 (en) | 1997-05-14 | 1998-05-14 | Methods and compositions for destruction of selected proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE69841549D1 true DE69841549D1 (de) | 2010-04-22 |
Family
ID=21943529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69841549T Expired - Lifetime DE69841549D1 (de) | 1997-05-14 | 1998-05-14 | Verfahren und zubereitungen zur zerstörung bestimmter proteine |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6670348B1 (enExample) |
| EP (1) | EP1023315B1 (enExample) |
| JP (2) | JP4903922B2 (enExample) |
| AT (1) | ATE460423T1 (enExample) |
| CA (1) | CA2287387C (enExample) |
| DE (1) | DE69841549D1 (enExample) |
| WO (1) | WO1998051702A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE473759T1 (de) * | 1998-05-22 | 2010-07-15 | Univ Leland Stanford Junior | Bifunktionelle moleküle sowie darauf basierende therapien. |
| WO2000045805A2 (en) * | 1999-02-08 | 2000-08-10 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Methods of inhibiting the hgf-met-upa-plasmin network with geldanamycin derivates |
| AU769235B2 (en) * | 1999-04-09 | 2004-01-22 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
| US7220552B1 (en) | 1999-11-19 | 2007-05-22 | The Board Of Trustees Of The Leland Stanford Junior University | Bifunctional molecules and their use in the disruption of protein-protein interactions |
| AU2044001A (en) | 1999-11-19 | 2001-05-30 | Board Of Trustees Of The Leland Stanford Junior University | Targeted bifunctional molecules and therapies based thereon |
| US6887842B1 (en) * | 1999-11-19 | 2005-05-03 | The Board Of Trustees Of The Leland Stanford Junior University | Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug |
| EP1322307B1 (en) * | 2000-07-28 | 2011-09-28 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| US7439359B2 (en) | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
| AU2002310065B2 (en) | 2001-05-23 | 2007-07-05 | Sloan Kettering Institute For Cancer Research | Method of treatment for cancers associated with elevated HER 2 levels |
| GB0117645D0 (en) * | 2001-07-19 | 2001-09-12 | Isis Innovation | Therapeutic stratergies for prevention and treatment of alzheimers disease |
| US6872715B2 (en) | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| WO2003037860A2 (en) | 2001-10-30 | 2003-05-08 | Conforma Therapeutics Corporation | Purine analogs having hsp90-inhibiting activity |
| ATE433961T1 (de) | 2002-02-08 | 2009-07-15 | Conforma Therapeutics Corp | Ansamycine mit verbesserten pharmakologischen und biologischen eigenschaften |
| US7230139B2 (en) | 2002-12-05 | 2007-06-12 | Gemin X Biotechnologies | Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents |
| KR101129215B1 (ko) | 2003-06-27 | 2012-04-13 | 교와 핫꼬 기린 가부시키가이샤 | Ｈｓｐ90 패밀리 단백질 저해제 |
| EA010160B1 (ru) | 2003-09-18 | 2008-06-30 | Конформа Терапьютикс Корпорейшн | Новые гетероциклические соединения - ингибиторы hsp90 и способы их получения |
| US7259156B2 (en) * | 2004-05-20 | 2007-08-21 | Kosan Biosciences Incorporated | Geldanamycin compounds and method of use |
| WO2006034147A2 (en) * | 2004-09-16 | 2006-03-30 | Abraxis Bioscience, Inc. | Compositions and methods for the preparation and administration of poorly water soluble drugs |
| MX2007004488A (es) * | 2004-10-13 | 2007-09-11 | Wyeth Corp | Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos. |
| MX2007004489A (es) * | 2004-10-13 | 2007-09-21 | Wyeth Corp | Analogos de 17-hidroxiwortamina como inhibidores pi3k. |
| KR20080004550A (ko) | 2005-03-30 | 2008-01-09 | 콘포마 세러퓨틱스 코포레이션 | Ｈｓｐ９０-억제제로서 알키닐 피롤로피리미딘 및 관련유사체 |
| EP1940386A4 (en) * | 2005-09-01 | 2010-06-23 | Beth Israel Hospital | WORDMAN'S CONJUGATES AND USES THEREOF |
| WO2007131034A1 (en) * | 2006-05-03 | 2007-11-15 | The Regents Of The University Of Michigan | Pyrimidone derivatives which are modulators of heat shock protein (hsp) 70 |
| JP5599610B2 (ja) | 2006-06-30 | 2014-10-01 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | Ｈｓｐ９０の阻害による神経変性疾患の処置 |
| JP5276020B2 (ja) * | 2007-02-13 | 2013-08-28 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | カチオン性エストラジオール誘導体、その合成方法、及び医薬組成物 |
| TW200845960A (en) * | 2007-04-05 | 2008-12-01 | Wyeth Corp | Wortmannin-rapalog conjugate and uses thereof |
| US20080249123A1 (en) * | 2007-04-05 | 2008-10-09 | Wyeth | Wortmannin-rapamycin conjugate and uses thereof |
| BR112012008019A2 (pt) | 2009-10-07 | 2016-03-01 | Sloan Kettering Inst Cancer | derivados de purina úteis como inibidores de hsp90 |
| AU2011272860A1 (en) | 2010-06-30 | 2013-02-07 | Brandeis University | Small-molecule-targeted protein degradation |
| EP2694505B1 (en) | 2011-04-05 | 2022-04-27 | Sloan-kettering Institute For Cancer Research | Hsp90 inhibitors |
| CA2832099C (en) | 2011-04-05 | 2019-07-09 | Sloan-Kettering Institute For Cancer Research | Hsp90 inhibitors |
| KR102438072B1 (ko) | 2012-01-12 | 2022-08-31 | 예일 유니버시티 | E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법 |
| EP2846784A4 (en) * | 2012-05-11 | 2016-03-09 | Univ Yale | COMPOUNDS FOR PROMOTING PROTEIN REMOVAL AND PROCESS THEREFOR |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| US11352351B2 (en) | 2015-01-20 | 2022-06-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| HK1249058A1 (zh) | 2015-03-18 | 2018-10-26 | Arvinas, Inc. | 用於增强靶向蛋白质降解的化合物和方法 |
| WO2016197114A1 (en) | 2015-06-05 | 2016-12-08 | Arvinas, Inc. | Tank-binding kinase-1 protacs and associated methods of use |
| US10772962B2 (en) | 2015-08-19 | 2020-09-15 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| WO2018053354A1 (en) | 2016-09-15 | 2018-03-22 | Arvinas, Inc. | Indole derivatives as estrogen receptor degraders |
| HUE070289T2 (hu) | 2016-10-11 | 2025-05-28 | Arvinas Operations Inc | Vegyületek és módszerek az androgénreceptor célzott lebontására |
| KR20230127371A (ko) | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| IL297717A (en) | 2016-12-01 | 2022-12-01 | Arvinas Operations Inc | History of tetrahydronaphthalene and tetrahydroisoquinoline as estrogen receptor antagonists |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| WO2018118598A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| MX2019007649A (es) | 2016-12-23 | 2019-09-10 | Arvinas Operations Inc | Compuestos y metodos para la degradacion dirigida de polipeptidos de fibrosarcoma acelerado rapidamente. |
| WO2018119441A1 (en) | 2016-12-23 | 2018-06-28 | Arvinas, Inc. | Egfr proteolysis targeting chimeric molecules and associated methods of use |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| IL300417A (en) | 2017-01-26 | 2023-04-01 | Arvinas Operations Inc | Bifunctional benzothiophene compounds, preparations containing them and their use in therapy |
| EP3577109A4 (en) | 2017-01-31 | 2020-11-18 | Arvinas Operations, Inc. | CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| EP3743066A4 (en) | 2018-01-26 | 2021-09-08 | Yale University | IMIDE-BASED PROTEOLYSIS MODULATORS AND RELATED METHODS OF USE |
| JP7720698B2 (ja) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| WO2020206608A1 (en) * | 2019-04-09 | 2020-10-15 | Ranok Therapeutics (Hangzhou) Co., Ltd. | Methods and compositions for targeted protein degradation |
| US11912699B2 (en) | 2019-07-17 | 2024-02-27 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated |
| EP4021450B1 (en) | 2019-08-26 | 2025-11-05 | Arvinas Operations, Inc. | Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders |
| AU2020368542B2 (en) | 2019-10-17 | 2024-02-29 | Arvinas Operations, Inc. | Bifunctional molecules containing an E3 ubiquitine ligase binding moiety linked to a BCL6 targeting moiety |
| AU2020405129A1 (en) | 2019-12-19 | 2022-06-23 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| MX2022014071A (es) | 2020-05-09 | 2023-01-30 | Arvinas Operations Inc | Metodos para fabricar un compuesto bifuncional, formas ultrapuras del compuesto bifuncional y formas de dosificacion que comprenden el mismo. |
| EP4204418A1 (en) | 2020-08-28 | 2023-07-05 | Arvinas Operations, Inc. | Rapidly accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| EP4211128A1 (en) | 2020-09-14 | 2023-07-19 | Arvinas Operations, Inc. | Crystalline forms of a compound for the targeted degradation of estrogen receptor |
| EP4323352A1 (en) | 2021-04-16 | 2024-02-21 | Arvinas Operations, Inc. | Modulators of bcl6 proteolysis and associated methods of use |
| TW202432544A (zh) | 2022-09-07 | 2024-08-16 | 美商亞文納營運公司 | 快速加速纖維肉瘤降解化合物及相關使用方法 |
| TW202444727A (zh) | 2023-01-26 | 2024-11-16 | 美商艾維納斯手術有限公司 | 基於cereblon之kras降解protac及其相關用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| DE3907290A1 (de) * | 1989-03-07 | 1990-09-13 | Gerhard Prof Dr Eisenbrand | Steroidhormonrezeptoraffine antitumorwirkstoffe |
| US5650430A (en) | 1990-06-06 | 1997-07-22 | Sankyo Company, Limited | Radicicol derivatives, their preparation and their anti-tumor activity |
| AU6803494A (en) * | 1993-06-07 | 1995-01-03 | British Technology Group Limited | Anticancer compounds |
| US5932566A (en) | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
| US5911995A (en) * | 1994-08-19 | 1999-06-15 | Regents Of The University Of Minnesota | EGF-genistein conjugates for the treatment of cancer |
| AU6267896A (en) * | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
| ATE266017T1 (de) | 1996-10-25 | 2004-05-15 | Kyowa Hakko Kogyo Kk | Radicicolderivate |
| US5968921A (en) * | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
-
1998
- 1998-05-14 JP JP54951698A patent/JP4903922B2/ja not_active Expired - Fee Related
- 1998-05-14 DE DE69841549T patent/DE69841549D1/de not_active Expired - Lifetime
- 1998-05-14 AT AT98923415T patent/ATE460423T1/de not_active IP Right Cessation
- 1998-05-14 US US09/403,434 patent/US6670348B1/en not_active Expired - Fee Related
- 1998-05-14 WO PCT/US1998/009805 patent/WO1998051702A1/en not_active Ceased
- 1998-05-14 CA CA2287387A patent/CA2287387C/en not_active Expired - Fee Related
- 1998-05-14 EP EP98923415A patent/EP1023315B1/en not_active Expired - Lifetime
-
2009
- 2009-08-11 JP JP2009186660A patent/JP2009256388A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998051702A1 (en) | 1998-11-19 |
| ATE460423T1 (de) | 2010-03-15 |
| JP2009256388A (ja) | 2009-11-05 |
| JP4903922B2 (ja) | 2012-03-28 |
| JP2001525824A (ja) | 2001-12-11 |
| EP1023315A1 (en) | 2000-08-02 |
| EP1023315A4 (en) | 2004-12-29 |
| CA2287387C (en) | 2010-02-16 |
| US6670348B1 (en) | 2003-12-30 |
| EP1023315B1 (en) | 2010-03-10 |
| CA2287387A1 (en) | 1998-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69841549D1 (de) | Verfahren und zubereitungen zur zerstörung bestimmter proteine | |
| WO2003030934A3 (en) | Cpg formulations and related methods | |
| ATE365562T1 (de) | Zielgerichtete kombinations-immuntherapie für krebs | |
| DE69910216D1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| PT983087E (pt) | Composicao de vacina multivalente com veiculo misto | |
| BR0312421A (pt) | Uso de inibidores de cept e opcionalmente inibidores hmg coa redutase e/ou agentes anti-hipertensivos | |
| BR0309875A (pt) | métodos e composições para tratamento de distúrbios do sistema nervoso periférico e novos compostos úteis para isto | |
| BR0312456A (pt) | Anticorpo alterado ou fragmento funcional do mesmo, polinucleotìdeo, sequência de polinucleotìdeo, composição farmacêutica, métodos de tratamento ou profilaxia de derrame e outras doenças/distúrbios neurológicos em um ser humano, de inibição da neurodegeneração e/ou promoção da recuperação funcional e de promoção do desenvolvimento axonial, e, uso de um anticorpo anti-mag | |
| DE60006280D1 (de) | Beta 2 -adrenergische rezeptor-agonisten | |
| EP1423107A4 (en) | FATTY ALCOHOL DRUG CONJUGATES | |
| BR0011000A (pt) | Métodos para prevenir ou tratar uma doença associada com depósitos amilóides de ab no cérebro de um paciente, para avaliar um anticorpo quanto á atividade de remoção de uma entidade biológica fisicamente associada com um antìgeno e para detectara um depósito amilóide em um paciente, composição farmacêutica, e, conjunto de diagnóstico | |
| AU2003218989A1 (en) | Tricyclic pyrazole derivatives, process for their preparation and their use as antitumor agents | |
| ES2110097T3 (es) | Sistema de liberacion basado en proteinas. | |
| BR0212841A (pt) | Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém | |
| DK0841949T3 (da) | Anvendelse af saccharid-konjugater | |
| NO20004803L (no) | Smilagening og anzurogenin for behandling av Alzheimers sykdom | |
| DE60033649D1 (de) | Verbindungen und therapeutische methoden | |
| ATE279390T1 (de) | Neue prodrugs von 6-hydroxy-2,3-dihydro-1h- indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo 3,2- e)indolen und 5-hydroxy-1,2-dihydro-3h-benzo e)indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro- benzo f)chinolin-derivaten für eine selektive krebstherapie | |
| BR0207487A (pt) | Método de tratamento de tumores em mamìferos e uso de compostos de epotilona | |
| MA58646A1 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| BR0111892A (pt) | Bis-arilsulfonas | |
| BR0009472A (pt) | Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas | |
| BR0010151A (pt) | Inibidores do sistema de clivagem de glicina como antipsicóticos potenciais | |
| WO2000078795A3 (en) | Rufomycins and derivatives thereof useful as inhibitors of multi-drug resistance associated protein-1 (mrp-1) | |
| BR9908716A (pt) | Tratamento de disfunção sexual em certos grupos de pacientes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |